Atara Biotherapeutics, INC (NASDAQ: ATRA), which nine analysts track, has been given an average rating of “Hold” by these analysts, as reported by Bloomberg.com.
These evaluations are derived from the stock price of the company.
Two research analysts have recommended selling the stock, three have recommended holding onto the stock, and three experts have recommended purchasing the stock.
The brokerage firms that rated the company’s shares during the previous year had an average one-year target price of $19.25 per share.
On February 8th, the most recent earnings report for Atara Biotherapeutics was made public.
Atara Biotherapeutics shares are traded on the NASDAQ under the ticker symbol ATRA.
The biotechnology company’s quarterly profits per share came in at $0.60, $0.11 less than the consensus estimate of $0.61.
The revenue for the quarter came in at $0.22 million, which was a significant drop from the $60.00 million that analysts had anticipated the quarter to bring in.
Atara Biotherapeutics had a return on equity of 140.05 percent, but the company had a negative net margin of 359.12 percent.
According to forecasts provided by analysts in the relevant industry, Atara Biotherapeutics is anticipated to finish the current financial year with earnings per share in the negative amount of $2.17.
ATRA shares began trading for the first time on Thursday, and the price per share started at $3.08.
The company has a price-to-earnings ratio of -1.38, a beta value of 0.99, and a market capitalization of $295.46 million.
The company has experienced a moving average of $4.12 over the previous 200 days; the moving average for the previous 50 days is $4.14. Over the past year, the price of Atara Biotherapeutics has fluctuated quite a bit, reaching an all-time low of $2.66 and an all-time high of $10.01.
Recent articles covering the ATRA stock were published in several different analyst sources.
I reaffirmed my “buy” rating on shares of Atara Biotherapeutics and established a price objective of $25.00 for the company in a research note published on Thursday, February 9th.
Atara Biotherapeutics was singled out for investment consideration by HC Wainwright in a report on the company’s performance released on Thursday, February 9th, and given a “buy” recommendation.
The company’s initial projections indicated that the stock would reach a price of $29 per share at some point in the future.
Mizuho reaffirmed their “buy” rating on shares of Atara Biotherapeutics and set a price objective of $31.00 on the company’s stock in a research note published on February 7th.
The research note was about the company’s stock.
Pascal Touchon, the company’s Chief Executive Officer, sold 15,679 shares of the company’s stock on March 2nd, according to additional information related to this topic.
As a result of the sale of the shares at an average price of $3.63 per share, the total sales volume came to 56,914.77 dollars.
After the deal’s completion, the CEO will be the owner of 750,728 shares, each of which has a value of $2,725,142.64.
The company previously owned these shares.
Because of the filing made with the SEC, information regarding the transaction is now available to the general public. On the website of the SEC, you can locate this particular file.
Insiders of the company have sold 34,330 shares of company stock during the most recent three months for a total price of $129,165.
The employees and management of the company own a combined total of 4% of the total shares issued by the company.
According to ATRA, there have been recent shifts in the positions of several hedge funds and other institutional investors. Other types of institutional investors include pension funds and endowments.
By the end of the fourth quarter, the amount of stock in Atara Biotherapeutics that Voya Investment Management LLC owned reached 95.1% of the company’s total holdings. Voya Investment Management LLC now holds 69,150 shares of the biotechnology company’s stock, currently valued at $227,000, after purchasing an additional 33,714 shares during the period in question.
In the last three months of 2018, Josh Arnold Investment Consultant LLC made a 73.3% increase in the number of shares of Atara Biotherapeutics that were a part of its portfolio.
In the most recent quarter, Josh Arnold Investment Consultant LLC increased its holdings in the biotechnology company by purchasing an additional 22,000 shares.
As a result, the firm now owns 52,000 shares of stock in the company, valued at $171,000; In the fourth quarter of 2018, AllianceBernstein L.P.
Increased the amount of Atara Biotherapeutics stock that is owned by an additional 11.8%.
Alliancebernstein L.P.
Increased its total holdings to 119,640 after purchasing an additional 12,600 shares during the quarter.
This brings the value of the stock it owns in the biotechnology business to $392,000 and its total holdings to 119,640 shares.
During the final three months of 2018, Point72 Middle East FZE was responsible for Atara Biotherapeutics’ hiring of a new worker at a total cost of approximately 114,000 dollars.
During the final three months of 2018, Jane Street Group LLC increased the amount of Atara Biotherapeutics stock owned by 2,188.7%.
Throughout the year, Jane Street Group LLC successfully acquired an additional 155,093 shares of stock held by the biotechnology company.
This brings the company’s total number of shares to 148,007, with a value of $485,000.